At a glance
ClinicalIndex Comparison Record- ✓Histologically or cytologically confirmed non-small cell lung cancer (NSCLC), Stage IIIA or IIIB
- ✓Candidate for curative radiotherapy
- ✓Not a candidate for concurrent chemotherapy and radiotherapy
- ✓Age ≥18 years
- ✕Stage IV disease by imaging (bone scan, PET, brain MRI, chest CT)
- ✕Malignant pleural effusion (suspected or proven)
- ✕No surgical treatment available
- ✕Idiopathic pulmonary fibrosis
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Cetuximab (C225) and Radiation in Elderly and /or Poor Performance Status Patients With Locally Advanced Non-Small Cell Lung Cancer: A Phase II Study to Evaluate Survival and Toxicity
In Brief
A Phase 2 clinical trial evaluating cetuximab and radiation therapy for Lung Cancer. Completed, enrolled 58 participants across 175 sites.
Detailed Summary
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Cetuximab may also stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving cetuximab together with radiation therapy may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving cetuximab together with radiation therapy works in treating patients with stage III non-small cell lung cancer.